Vol. 6 No. 9 (2026): September
Reimbursement Reviews

Iptacopan (Fabhalta)

decorative image of the issue cover

Published September 14, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Iptacopan (Fabhalta), 200 mg, hard capsules, oral.
  • Indication: For the treatment of adult patients with C3G to reduce proteinuria.